Jump to content

Talk:Gilead Sciences: Difference between revisions

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
AnomieBOT (talk | contribs)
Bots
6,558,395 edits
Qwertz1894 (talk | contribs)
459 edits
mNo edit summary
Line 3: Line 3:
{{WikiProject California|sfba=yes|class=C|importance=Low|sfba-importance=Low}}
{{WikiProject California|sfba=yes|class=C|importance=Low|sfba-importance=Low}}
{{WikiProject Chemical and Bio Engineering|class=C|importance=Low}}
{{WikiProject Chemical and Bio Engineering|class=C|importance=Low}}
{{WikiProject Companies|class=C|importance=Low}}
{{WikiProject Companies|class=C|importance=High}}
}}
}}
{{Archives|collapsed=yes|image=none|search=no|large=yes}}
{{Archives|collapsed=yes|image=none|search=no|large=yes}}

Revision as of 21:51, 19 September 2020

The hyperlink to Micheal Riordan is wrong. The statement says he was a 29-year old doctor when the company was founded, and that the company was found in 1987. The hyperlinked article is for a Micheal Riordan who was an attorney and police officer and who died in 1967.

Impressive importation of Gilead's website

Hm, I had removed this back in November, and here it is back again.

These tables are impressive importations of Gilead's website but this we don't rebuild company websites in Wikipedia.

This is not encyclopedic content, in my view. Not (as in WP:NOT) what we do here. It is definitely something that can be done here.

Am well aware that company websites always include this content. Of course they do.

Ref #1 is fake - the FDA drug search page. Ref #2 only covers 13 products and is of course an SEC filing. Ref #3 is.. the company website.

So this is entirely OR. A work of love, but not valid here in WP.

Product portfolio

Gilead has 21 products on the market.

Product Portfolio
Brand Name Drug Name(s) Indication Date Approved (USA)[1] Marketing Partner(s) U.S. Patent Expiration[2] European Patent Expiration[2]
AmBisome liposomal amphotericin B fungal infection, cryptococcal meningitis, Aspergillus, Candida, Cryptococcus infections 1997-08-11 Astellas Pharma(USA)Rapiscan(EU) 2016 expired
Atripla tenofovir, emtricitabine, and efavirenz HIV, AIDS 2006-07-12 Bristol-Myers Squibb 2021 2018
Cayston Aztreonam Cystic Fibrosis 2010-02-22 2021 2021
Descovy Emtricitabine/tenofovir alafenamide 2016-04-04
Epclusa Velpatasvir/sofosbuvir Hepatitis C 2016-06-28
Complera/Eviplera tenofovir, emtricitabine, and rilpivirine HIV, AIDS 2011-08-10 Johnson and Johnson  
Emtriva emtricitabine HIV, AIDS 2003-07-02   2021 2016
Flolan epoprostenol sodium pulmonary hypertension 1995-09-20 GlaxoSmithKline expired expired
Genvoya Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 2015-11-05
Harvoni sofosbuvir, ledipasvir Hepatitis C 2014-10-10
Hepsera adefovir dipivoxil hepatitis B (HBV) 2002-09-20   2014 2011
Letairis ambrisentan Pulmonary arterial hypertension 2007-06-15 GlaxoSmithKline 2015 2015
Lexiscan regadenoson myocardial perfusion imaging 2008-04-10 Astellas 2019 2020
Macugen pegaptanib sodium solution age-related macular degeneration 2004-12-17 OSI and Pfizer 2017 2017
Odefsey Emtricitabine/rilpivirine/tenofovir alafenamide 2016-03-01
Ranexa ranolazine angina 2006-01-27 Hoffmann–La Roche 2019 2019
Sovaldi sofosbuvir Hepatitis C 2013-12-06
Stribild elvitegravir, cobicistat, emtricitabine, tenofovir HIV, AIDS 2012-08-27
Tamiflu oseltamivir phosphate influenza 1999-10-27 Hoffmann–La Roche 2016 2016
Truvada emtricitabine and tenofovir HIV, AIDS 2004-08-02   2021 2018
Tybost cobicistat HIV, AIDS 2013-09-25 (EU), 2014-09-24 (US)
Vemlidy Tenofovir alafenamide 2016-11-10
Viread tenofovir HIV, AIDS, hepatitis B 2001-10-26   2017 2018
Vistide cidofovir CMV retinitis 1996-06-26 Pfizer expired expired
Vitekta elvitegravir HIV, AIDS 2013-09-25 (EU), 2014-09-24 (US)
Zydelig idelalisib oncology, lymphoma 2014-07-23
Pipeline

Phase II and III drugs currently in development include:[3]

References

  1. ^ "Drugs@FDA: FDA Approved Drug Products". Food and Drug Administration. Retrieved 2011-01-15.
  2. ^ a b Gilead Sciences (2010-03-01). "2009 Form 10-K Annual Report". SEC. Retrieved 2011-01-15.
  3. ^ http://www.gilead.com/research/pipeline

-- Jytdog (talk) 14:44, 31 August 2017 (UTC)[reply]

1992 prospectus

Would love to find an RS for their IPO. SEC EDGAR only goes back to 94... Scribd is not OK. 15:11, 31 August 2017 (UTC)

Whistleblower Lawsuit

After reading an article on Ars Technica I jumped straight here to see if there was any mention of the whistleblower lawsuit related to contaminated emtricitabine made in China and there was none. Isn't this relevant enough to be recorded here? The best news article I found about it is this one here, but I'm not familiar with Wikipedia's customs and protocols on editing an article (I just created my account after years of just reading it). Marshal banana 1983 (talk) 17:25, 8 January 2019 (UTC)[reply]

Potential RS

Out of an abundance of caution, I am adding content to the talk page before editing the article directly: By March 2020, Gilead Sciences (GILD) was making a substantial profit mainly because of its $17 billion HIV franchise and its HCV portfolio, which includes HCV drugs, such as Sovaldi and Harvoni, according to a Morningstar article.[1] The sale of these two HCV drugs peaked at more than $19 billion in 2015. Gilead had acquired Sovaldi when it purchased Pharmasset in November 2011 for $11.2 billion.[2] $11 billion Pharmasset deal brought key HCV drug Sovaldi. Sovaldi and Harvoni (a combination of Sovaldi and ledipasvir) peaked at more than $19 billion in sales in 2015. HCV portfolio. Both HIV and HCV medications are inexpensive to manufacture and easy to market.[1]Oceanflynn (talk) 18:58, 15 March 2020 (UTC)[reply]

By 24 January 2020, Gilead had provided remdesivir during the 2019–20 coronavirus outbreak for a "small number of patients" in collaboration with Chinese medical authorities for studying its effects.[3] Later in January 2020, the first US patient received remdesivir in Snohomish County, Washington, and a 5 March 2020 article in the New England Journal of Medicine (NEJM) reported that patient showed improvement after taking Remdesivir.[4][5]

By late January, Chinese medical researchers involved in exploratory research in which they were considering a selection of 30 drug candidates. At that time, remdesivir was one of three drugs, along with chloroquine and lopinavir/ritonavir, that seemed to have "fairly good inhibitory effects" on SARS-CoV-2 at the cellular level. They requested permission to start clinical testing were submitted.[6][7]

The government-run Wuhan Institute of Virology, a member of the "elite Chinese Academy of Sciences" and the Military Medicine Institute[8] applied to patent Gilead's remdesivir in China on 21 January to treat COVID-19.[9][10] Wuhan Institute is located in the city of Wuhan—the center of the COVID-19 outbreak in China.[9] This could fuel "conflict over technology policy that helped trigger Washington’s tariff war with Beijing."[9] On 29 January, the Wuhan Institute applied for a "military laboratory". An institute statement from the Wuhan Institute of Virology "acknowledged there were "intellectual property barriers" but said it acted to "protect national interests."[9] On 31 January, access to Wuhan was suspended by the Chinese government.[9] Under the World Trade Organization rules China has the right to "declare an emergency and compel a company to license a patent to protect the public."[9]

At a WHO-China Joint Mission on COVID-19 press conference on 24 February evening in Beijing, the Assistant Director-general of the World Health Organization (WHO), Bruce Aylward, said that, "There’s only one drug right now that we think may have real efficacy. And that's Remdesivir".[11]: 14 [12] In response, by the end of February, Gilead's stocks had risen by $16 billion.[13]

In a 4 March 2020 article in Nature, scientists from the Wuhan Institute and the Military Medicine Institute reported that they "found both Remdesivir and Chloroquine, which is used to treat malaria, to be an effective way to inhibit the coronavirus."[14][9]

In a 6 March article, Reuters said that the Wuhan Institute "would temporarily drop its patent claims if the opportunity arose to collaborate with foreign pharmaceutical firms to fight the epidemic."[10]

The official Xinhua News Agency said "clinical trials of the drug, remdesivir, would start" in China on 6 February 2020.[9][15] In a 14 February article, FiercePharmacy said that Chinese drugmaker BrightGene had successfully "mass produced remdesivir's active ingredient" and was producing finished doses. BrightGene said the "final marketing requires a license from Gilead, the patent holder.[16]

According to a 11 March 2020 The Washington Post article, while remdesivir had successfully blocked the "Ebola virus in laboratories and in animal experiments", researchers decided in August to stop using it on human patients because "it did such a bad job extending survival in humans compared to two of the other treatments."[17] A 2016 article in the journal Nature , said that a group of scientists had found that the antiviral drug that Gilead had developed—Remdesivir—had been effective against the Ebola virus disease in rhesus monkeys.[18] In a 6 February 2020 Associated Press article, Gilead said that said it had applied for a for a "Chinese patent" on the "use of remdesivir against coronaviruses" in 2016 and was still "waiting for a decision."[9]

A June 2017 article in the journal Science Translational Medicine reported that remdesivir was "shown to be active" against SARS and MERS in animals in laboratory tests.[19][20]

Statsnews reported on the March 2020 RBC Capital Markets analysts in response to their investigation of data from a study undertaken by the Centers for Disease Control and Prevention Covid-19 response team on the first 12 patients with COVID-19 in the United States. The RBC analysts said that Remdesivir produced "mixed results" with "less than 50/50 possibility that the drug is ultimately proven effective." The analysts mentioned concerns about Remdesivir's side effects.[21]

In February, China began to use chloroquine phosphate, a "structural analogue of quinine, originally extracted from the bark of cinchona trees" to treat COVID-19 patients.[22]

References

  1. ^ a b Andersen, Karen (13 March 2020). "Portfolio and Pipeline Set Gilead Apart". Morningstar, Inc. Retrieved 15 March 2020.
  2. ^ Tom Murphy (November 21, 2011). "Gilead Sciences to buy Pharmasset for $11 billion". Bloomberg Businessweek.
  3. ^ Taylor, Nick Paul (24 January 2020). "Gilead mulls repositioning failed Ebola drug in China virus". Fierce Biotech. Retrieved 31 January 2020.
  4. ^ Holshue, Michelle L.; DeBolt, Chas; Lindquist, Scott; Lofy, Kathy H.; Wiesman, John; Bruce, Hollianne; Spitters, Christopher; Ericson, Keith; Wilkerson, Sara; Tural, Ahmet; Diaz, George; Cohn, Amanda; Fox, LeAnne; Patel, Anita; Gerber, Susan I.; Kim, Lindsay; Tong, Suxiang; Lu, Xiaoyan; Lindstrom, Steve; Pallansch, Mark A.; Weldon, William C.; Biggs, Holly M.; Uyeki, Timothy M.; Pillai, Satish K. (5 March 2020). "First Case of 2019 Novel Coronavirus in the United States". New England Journal of Medicine. 382 (10): 929–936. doi:10.1056/NEJMoa2001191. ISSN 0028-4793. PMID 32004427. Retrieved 15 March 2020.
  5. ^ Harmon, Amy (5 February 2020). "Inside the Race to Contain America's First Coronavirus Case". The New York Times. ISSN 0362-4331. Retrieved 7 February 2020.
  6. ^ Zhao, Yuning (2020-01-30). "Three drugs fairly effective on novel coronavirus at cellular level". China News Service. Archived from the original on 2020-01-29. Retrieved 2020-02-01. {{cite web}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
  7. ^ Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. (March 2020). "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Cell Research. 30 (3): 269–271. doi:10.1038/s41422-020-0282-0. PMID 32020029.
  8. ^ Schmitt & Orlov (10 March 2020). "Wuhan institute of virology filed patent application for remdesivir use in fight against 2019-ncov". Lexology. Retrieved 15 March 2020.
  9. ^ a b c d e f g h i "China scientists want to patent Gilead drug to treat coronavirus patients". Associated Press via MarketWatch. Beijing. 6 February 2020. Retrieved 15 March 2020.
  10. ^ a b "China lab seeks patent on use of Gilead's coronavirus treatment". Reuters. 5 February 2020. Retrieved 15 March 2020.
  11. ^ Press Conference of WHO-China Joint Mission on COVID-19 (PDF), Beijing, 24 February 2020, retrieved 15 March 2020{{citation}}: CS1 maint: location missing publisher (link)
  12. ^ Armstrong, Drew; Lipschultz, Bailey (24 February 2020), "Gilead Surges After WHO Comments on Virus Drug Testing", Bloomberg, retrieved 15 March 2020
  13. ^ Flanagan, Christine (27 February 2020). "Gilead's $16 Billion Virus-Fueled Jump Draws Warning of Fall". Bloomberg. Retrieved 15 March 2020.
  14. ^ Wang, Manli; Cao, Ruiyuan; Zhang, Leike; Yang, Xinglou; Liu, Jia; Xu, Mingyue; Shi, Zhengli; Hu, Zhihong; Zhong, Wu; Xiao, Gengfu (4 March 2020). "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Cell Research. 30 (3): 269–271. doi:10.1038/s41422-020-0282-0. ISSN 1748-7838. Retrieved 15 March 2020.
  15. ^ Grady, Denise (6 February 2020). "China Begins Testing an Antiviral Drug in Coronavirus Patients". The New York Times. ISSN 0362-4331. Retrieved 7 February 2020.
  16. ^ Liu, Angus (14 February 2020). "FiercePharmaAsia—Gilead remdesivir's copy". Fierce Pharma Asia. Retrieved 15 March 2020.
  17. ^ Rowland, Christopher (11 March 2020). "The best hope for coronavirus treatment is an experimental drug that fizzled against Ebola". Washington Post. Retrieved 15 March 2020.
  18. ^ Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (March 2016). "Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys". Nature. 531 (7594): 381–5. Bibcode:2016Natur.531..381W. doi:10.1038/nature17180. PMC 5551389. PMID 26934220.
  19. ^ Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. (June 2017). "Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses". Science Translational Medicine. 9 (396): eaal3653. doi:10.1126/scitranslmed.aal3653. PMC 5567817. PMID 28659436.
  20. ^ Joseph, Saumya Sibi; Samuel, Maju (2020-01-31). "Gilead working with China to test Ebola drug as new coronavirus treatment". Thomson Reuters. Archived from the original on 2020-01-31. Retrieved 2020-01-31. {{cite news}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
  21. ^ Silverman, Ed (13 March 2020). "New paper about a Gilead drug to combat coronavirus has analysts skittish". Retrieved 15 March 2020.
  22. ^ "Redeploying plant defences". Nature Plants. 6 (3): 177–177. March 2020. doi:10.1038/s41477-020-0628-0. ISSN 2055-0278. Retrieved 15 March 2020.

Oceanflynn (talk) 19:35, 15 March 2020 (UTC)[reply]

@Oceanflynn: Hmm no replies, that's odd; and your stuff does not seem to have been incorporated in the article. Did you simply move on to other endeavours? —Jerome Potts (talk) 21:32, 25 June 2020 (UTC)[reply]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Talk:Gilead_Sciences&oldid=979283410"